A Gilead Sciences workplace is proven in Foster City, California, U.S. May 1, 2018.
Stephen Lam | Reuters
Gilead Sciences Inc is nearing a deal to purchase biopharmaceutical firm Immunomedics Inc for greater than $20 billion in a deal that might additional develop Gilead’s portfolio of most cancers remedies, the Wall Street Journal reported on Saturday.
A deal for Immunomedics, whose most cancers remedy Trodelvy is FDA-approved as a third-line remedy for an aggressive kind of breast most cancers referred to as Metastatic Triple-Negative Breast Cancer, may very well be introduced Monday if not sooner, the Journal mentioned, citing folks accustomed to the matter.
Discussions between Gilead and Immunomedics have been initially centered round a partnership earlier than shifting to a full-fledged takeover negotiation, the Journal added.
Gilead and Immunomedics didn’t reply instantly to emailed requests from Reuters for remark.
Shares of Immunomedics, which final month reported constructive information from a late-stage confirmatory research for Trodelvy, have almost doubled this yr, giving the corporate a valuation of near $10 billion.
An acquisition of Immunomedics would add to a number of offers Gilead inked this yr with the purpose of increasing its oncology portfolio.
It purchased a 49.9% stake in most cancers drug developer Pionyr Immunotherapeutics in June for $275 million, simply months after paying $4.9 billion for Forty Seven Inc, maker of an experimental remedy that targets blood most cancers.